Corvus Pharmaceuticals, Inc. Operating Income
Corvus Pharmaceuticals, Inc. (CRVS) reported Operating Income of -$19.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$19.30M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$14.88M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$12.22M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$10.57M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$42.97M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$27.55M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$23.41M.
- Corvus Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$32.56M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 11 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$19.30M 10-Q · filed 2026-08-06 | -$34.17M 10-Q · filed 2026-08-06 | -$46.39M derived: sum of 3 quarters · filed 2026-08-06 | -$56.96M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$14.88M 10-Q · filed 2026-05-07 | -$27.09M derived: sum of 2 quarters · filed 2026-05-07 | -$37.67M derived: sum of 3 quarters · filed 2026-05-07 | -$47.93M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$12.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$22.79M derived: sum of 2 quarters · filed 2026-03-12 | -$33.05M derived: sum of 3 quarters · filed 2026-08-06 | -$42.97M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$10.57M 10-Q · filed 2025-11-04 | -$20.83M derived: sum of 2 quarters · filed 2026-08-06 | -$30.75M 10-Q · filed 2025-11-04 | -$38.86M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$10.26M 10-Q · filed 2026-08-06 | -$20.18M 10-Q · filed 2026-08-06 | -$28.29M derived: sum of 3 quarters · filed 2026-08-06 | -$35.54M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$9.92M 10-Q · filed 2026-05-07 | -$18.03M derived: sum of 2 quarters · filed 2026-05-07 | -$25.28M derived: sum of 3 quarters · filed 2026-05-07 | -$31.22M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$15.36M derived: sum of 2 quarters · filed 2026-03-12 | -$21.30M derived: sum of 3 quarters · filed 2026-03-12 | -$27.55M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$7.25M 10-Q · filed 2025-11-04 | -$13.19M derived: sum of 2 quarters · filed 2025-11-04 | -$19.44M 10-Q · filed 2025-11-04 | -$25.09M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | -$5.93M 10-Q · filed 2025-08-07 | -$12.19M 10-Q · filed 2025-08-07 | -$17.84M derived: sum of 3 quarters · filed 2026-03-12 | -$23.40M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | -$6.25M 10-Q · filed 2025-05-08 | -$11.90M derived: sum of 2 quarters · filed 2026-03-12 | -$17.46M derived: sum of 3 quarters · filed 2026-03-12 | -$23.09M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | -$5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$11.21M derived: sum of 2 quarters · filed 2026-03-12 | -$16.83M derived: sum of 3 quarters · filed 2026-03-12 | -$23.41M 10-K · filed 2026-03-12 | |
| 2023-09-30 | -$5.56M 10-Q · filed 2024-11-12 | -$11.18M derived: sum of 2 quarters · filed 2024-11-12 | -$17.76M 10-Q · filed 2024-11-12 | -$23.42M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-06-30 | -$5.62M 10-Q · filed 2024-08-06 | -$12.20M 10-Q · filed 2024-08-06 | -$17.86M derived: sum of 3 quarters · filed 2025-03-25 | -$30.34M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-03-31 | -$6.57M 10-Q · filed 2024-05-07 | -$12.24M derived: sum of 2 quarters · filed 2025-03-25 | -$24.71M derived: sum of 3 quarters · filed 2025-03-25 | -$31.73M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2022-12-31 | -$5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$18.14M derived: sum of 2 quarters · filed 2025-03-25 | -$25.15M derived: sum of 3 quarters · filed 2025-03-25 | -$32.56M 10-K · filed 2025-03-25 | |
| 2022-09-30 | -$12.47M 10-Q · filed 2023-11-07 | -$19.49M derived: sum of 2 quarters · filed 2023-11-07 | -$26.90M 10-Q · filed 2023-11-07 | -$33.71M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | -$7.01M 10-Q · filed 2023-08-08 | -$14.43M 10-Q · filed 2023-08-08 | -$21.24M derived: sum of 3 quarters · filed 2024-03-19 | -$30.28M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | -$7.41M 10-Q · filed 2023-05-08 | -$14.22M derived: sum of 2 quarters · filed 2024-03-19 | -$23.27M derived: sum of 3 quarters · filed 2024-03-19 | -$34.56M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | -$6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$15.86M derived: sum of 2 quarters · filed 2024-03-19 | -$27.15M derived: sum of 3 quarters · filed 2024-03-19 | -$38.63M 10-K · filed 2024-03-19 | |
| 2021-09-30 | -$9.05M 10-Q · filed 2022-11-03 | -$20.34M derived: sum of 2 quarters · filed 2022-11-03 | -$31.82M 10-Q · filed 2022-11-03 | -$41.70M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-06-30 | -$11.29M 10-Q · filed 2022-08-08 | -$22.77M 10-Q · filed 2022-08-08 | -$32.65M derived: sum of 3 quarters · filed 2023-03-28 | -$42.50M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-03-31 | -$11.48M 10-Q · filed 2022-05-05 | -$21.36M derived: sum of 2 quarters · filed 2023-03-28 | -$31.21M derived: sum of 3 quarters · filed 2023-03-28 | -$41.97M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2020-12-31 | -$9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$19.72M derived: sum of 2 quarters · filed 2023-03-28 | -$30.49M derived: sum of 3 quarters · filed 2023-03-28 | -$43.76M 10-K · filed 2023-03-28 | |
| 2020-09-30 | -$9.85M 10-Q · filed 2021-11-01 | -$20.61M derived: sum of 2 quarters · filed 2021-11-01 | -$33.88M 10-Q · filed 2021-11-01 | -$45.32M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | -$10.77M 10-Q · filed 2021-08-02 | -$24.04M 10-Q · filed 2021-08-02 | -$35.48M derived: sum of 3 quarters · filed 2022-03-10 | -$46.99M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | -$13.27M 10-Q · filed 2021-04-29 | -$24.71M derived: sum of 2 quarters · filed 2022-03-10 | -$36.22M derived: sum of 3 quarters · filed 2022-03-10 | -$49.82M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | -$11.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$22.95M derived: sum of 2 quarters · filed 2022-03-10 | -$36.55M derived: sum of 3 quarters · filed 2022-03-10 | -$48.85M 10-K · filed 2022-03-10 | |
| 2019-09-30 | -$11.51M 10-Q · filed 2020-10-29 | -$25.11M derived: sum of 2 quarters · filed 2020-10-29 | -$37.41M 10-Q · filed 2020-10-29 | -$48.59M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-06-30 | -$13.60M 10-Q · filed 2020-07-30 | -$25.90M 10-Q · filed 2020-07-30 | -$37.07M derived: sum of 3 quarters · filed 2021-03-25 | -$48.22M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-03-31 | -$12.30M 10-Q · filed 2020-04-30 | -$23.48M derived: sum of 2 quarters · filed 2021-03-25 | -$34.63M derived: sum of 3 quarters · filed 2021-03-25 | -$46.88M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2018-12-31 | -$11.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$22.32M derived: sum of 2 quarters · filed 2021-03-25 | -$34.58M derived: sum of 3 quarters · filed 2021-03-25 | -$49.22M 10-K · filed 2021-03-25 | |
| 2018-09-30 | -$11.15M 10-Q · filed 2019-10-29 | -$23.41M derived: sum of 2 quarters · filed 2019-10-29 | -$38.05M 10-Q · filed 2019-10-29 | -$50.24M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-06-30 | -$12.26M 10-Q · filed 2019-08-01 | -$26.90M 10-Q · filed 2019-08-01 | -$39.09M derived: sum of 3 quarters · filed 2020-03-09 | -$52.03M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-03-31 | -$14.64M 10-Q · filed 2019-05-09 | -$26.83M derived: sum of 2 quarters · filed 2020-03-09 | -$39.78M derived: sum of 3 quarters · filed 2020-03-09 | -$54.95M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2017-12-31 | -$12.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$25.13M derived: sum of 2 quarters · filed 2020-03-09 | -$40.31M derived: sum of 3 quarters · filed 2020-03-09 | -$56.52M 10-K · filed 2020-03-09 | |
| 2017-09-30 | -$12.94M 10-Q · filed 2018-11-01 | -$28.12M derived: sum of 2 quarters · filed 2018-11-01 | -$44.34M 10-Q · filed 2018-11-01 | -$55.59M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | -$15.17M 10-Q · filed 2018-08-02 | -$31.39M 10-Q · filed 2018-08-02 | -$42.64M derived: sum of 3 quarters · filed 2019-03-07 | -$53.12M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | -$16.22M 10-Q · filed 2018-05-03 | -$27.47M derived: sum of 2 quarters · filed 2019-03-07 | -$37.94M derived: sum of 3 quarters · filed 2019-03-07 | -$46.77M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | -$11.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$21.73M derived: sum of 2 quarters · filed 2019-03-07 | -$30.55M derived: sum of 3 quarters · filed 2019-03-07 | -$36.98M 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$10.48M 10-Q · filed 2017-11-02 | -$19.30M derived: sum of 2 quarters · filed 2017-11-02 | -$25.73M 10-Q · filed 2017-11-02 | -$31.83M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | -$8.82M 10-Q · filed 2017-08-03 | -$15.25M 10-Q · filed 2017-08-03 | -$21.36M derived: sum of 3 quarters · filed 2018-03-01 | -$24.48M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | -$6.43M 10-Q · filed 2017-05-04 | -$12.53M derived: sum of 2 quarters · filed 2018-03-01 | -$15.65M derived: sum of 3 quarters · filed 2018-03-01 | -$17.98M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$9.22M derived: sum of 2 quarters · filed 2018-03-01 | -$11.56M derived: sum of 3 quarters · filed 2018-03-01 | -$13.77M 10-K · filed 2018-03-01 | |
| 2015-09-30 | -$3.12M 10-Q · filed 2016-11-03 | -$5.45M derived: sum of 2 quarters · filed 2016-11-03 | -$7.67M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | -$2.33M 10-Q · filed 2016-08-04 | -$4.55M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$2.21M 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | -$161.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |